BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Turner NA, Moake J. Assembly and activation of alternative complement components on endothelial cell-anchored ultra-large von Willebrand factor links complement and hemostasis-thrombosis. PLoS One 2013;8:e59372. [PMID: 23555663 DOI: 10.1371/journal.pone.0059372] [Cited by in Crossref: 71] [Cited by in F6Publishing: 62] [Article Influence: 7.9] [Reference Citation Analysis]
Number Citing Articles
1 Kremer Hovinga JA, Coppo P, Lämmle B, Moake JL, Miyata T, Vanhoorelbeke K. Thrombotic thrombocytopenic purpura. Nat Rev Dis Primers 2017;3. [DOI: 10.1038/nrdp.2017.20] [Cited by in Crossref: 105] [Cited by in F6Publishing: 97] [Article Influence: 21.0] [Reference Citation Analysis]
2 Geramita MA, Hofer J, Cooper J, Moritz ML. Decreased severity of Shiga toxin-producing Escherichia coli haemolytic uraemic syndrome (STEC-HUS) in a child with type 1 von Willebrand disease. BMJ Case Rep 2017;2017:bcr-2017-221043. [PMID: 28855217 DOI: 10.1136/bcr-2017-221043] [Reference Citation Analysis]
3 Meraz-Ríos MA, Majluf-Cruz A, Santana C, Noris G, Camacho-Mejorado R, Acosta-Saavedra LC, Calderón-Aranda ES, Hernández-Juárez J, Magaña JJ, Gómez R. Association of vWA and TPOX polymorphisms with venous thrombosis in Mexican mestizos. Biomed Res Int 2014;2014:697689. [PMID: 25250329 DOI: 10.1155/2014/697689] [Cited by in Crossref: 3] [Article Influence: 0.4] [Reference Citation Analysis]
4 Oh J, Oh D, Lee SJ, Kim JO, Kim NK, Chong SY, Huh JY, Baker RI; Korean TTP Registry Investigators. Prognostic utility of ADAMTS13 activity for the atypical hemolytic uremic syndrome (aHUS) and comparison of complement serology between aHUS and thrombotic thrombocytopenic purpura. Blood Res 2019;54:218-28. [PMID: 31730685 DOI: 10.5045/br.2019.54.3.218] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
5 Chen YY, Han SS, Cao Y, Yu XJ, Zhu L, Luo JC, Song WC, Yu F, Mao YH, Zhao MH. von Willebrand factor variants in C3 glomerulopathy: A Chinese cohort study. Clin Immunol 2021;229:108794. [PMID: 34245915 DOI: 10.1016/j.clim.2021.108794] [Reference Citation Analysis]
6 Bettoni S, Galbusera M, Gastoldi S, Donadelli R, Tentori C, Spartà G, Bresin E, Mele C, Alberti M, Tortajada A, Yebenes H, Remuzzi G, Noris M. Interaction between Multimeric von Willebrand Factor and Complement: A Fresh Look to the Pathophysiology of Microvascular Thrombosis. J Immunol 2017;199:1021-40. [PMID: 28652401 DOI: 10.4049/jimmunol.1601121] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 5.0] [Reference Citation Analysis]
7 Noone DG, Riedl M, Pluthero FG, Bowman ML, Liszewski MK, Lu L, Quan Y, Balgobin S, Schneppenheim R, Schneppenheim S, Budde U, James P, Atkinson JP, Palaniyar N, Kahr WH, Licht C. Von Willebrand factor regulates complement on endothelial cells. Kidney Int 2016;90:123-34. [PMID: 27236750 DOI: 10.1016/j.kint.2016.03.023] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 5.3] [Reference Citation Analysis]
8 Conway EM. Complement-coagulation connections. Blood Coagul Fibrinolysis 2018;29:243-51. [PMID: 29517503 DOI: 10.1097/MBC.0000000000000720] [Cited by in Crossref: 23] [Cited by in F6Publishing: 14] [Article Influence: 5.8] [Reference Citation Analysis]
9 Gogoi D, Arora N, Kalita B, Sarma R, Islam T, Ghosh SS, Devi R, Mukherjee AK. Anticoagulant mechanism, pharmacological activity, and assessment of preclinical safety of a novel fibrin(ogen)olytic serine protease from leaves of Leucas indica. Sci Rep 2018;8:6210. [PMID: 29670183 DOI: 10.1038/s41598-018-24422-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
10 Karpman D, Ståhl AL, Arvidsson I, Johansson K, Loos S, Tati R, Békássy Z, Kristoffersson AC, Mossberg M, Kahn R. Complement Interactions with Blood Cells, Endothelial Cells and Microvesicles in Thrombotic and Inflammatory Conditions. Adv Exp Med Biol 2015;865:19-42. [PMID: 26306441 DOI: 10.1007/978-3-319-18603-0_2] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 4.1] [Reference Citation Analysis]
11 Noone DG, Riedl M, Licht C. The role of von Willebrand factor in thrombotic microangiopathy. Pediatr Nephrol 2018;33:1297-307. [DOI: 10.1007/s00467-017-3744-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
12 Nguyen TC. Thrombocytopenia-Associated Multiple Organ Failure. Crit Care Clin 2020;36:379-90. [PMID: 32172819 DOI: 10.1016/j.ccc.2019.12.010] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
13 van de Leemput J, Han Z. Drosophila, a powerful model to study virus-host interactions and pathogenicity in the fight against SARS-CoV-2. Cell Biosci 2021;11:110. [PMID: 34120640 DOI: 10.1186/s13578-021-00621-5] [Reference Citation Analysis]
14 Rauch A, Wohner N, Christophe OD, Denis CV, Susen S, Lenting PJ. On the versatility of von Willebrand factor. Mediterr J Hematol Infect Dis 2013;5:e2013046. [PMID: 23936617 DOI: 10.4084/MJHID.2013.046] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.2] [Reference Citation Analysis]
15 Michael M, Turner N, Elenberg E, Shaffer LG, Teruya J, Arar M, Hui SK, Smith RJ, Moake J. Deficiency of complement factor H-related proteins and autoantibody-positive hemolytic uremic syndrome in an infant with combined partial deficiencies and autoantibodies to complement factor H and ADAMTS13. Clin Kidney J 2018;11:791-6. [PMID: 30524124 DOI: 10.1093/ckj/sfy010] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
16 Sharma C, Salem GEM, Sharma N, Gautam P, Singh R. Thrombolytic Potential of Novel Thiol-Dependent Fibrinolytic Protease from Bacillus cereus RSA1. Biomolecules 2019;10:E3. [PMID: 31861284 DOI: 10.3390/biom10010003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
17 Pecoraro C, Ferretti AV, Rurali E, Galbusera M, Noris M, Remuzzi G. Treatment of Congenital Thrombotic Thrombocytopenic Purpura With Eculizumab. Am J Kidney Dis 2015;66:1067-70. [PMID: 26409664 DOI: 10.1053/j.ajkd.2015.06.032] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
18 Nguyen TC, Cruz MA, Carcillo JA. Thrombocytopenia-Associated Multiple Organ Failure and Acute Kidney Injury. Crit Care Clin 2015;31:661-74. [PMID: 26410136 DOI: 10.1016/j.ccc.2015.06.004] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 4.1] [Reference Citation Analysis]
19 Arvidsson I, Rebetz J, Loos S, Herthelius M, Kristoffersson A, Englund E, Chromek M, Karpman D. Early Terminal Complement Blockade and C6 Deficiency Are Protective in Enterohemorrhagic Escherichia coli– Infected Mice. J I 2016;197:1276-86. [DOI: 10.4049/jimmunol.1502377] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
20 Kremer Hovinga JA, Heeb SR, Skowronska M, Schaller M. Pathophysiology of thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. J Thromb Haemost 2018;16:618-29. [DOI: 10.1111/jth.13956] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 4.8] [Reference Citation Analysis]
21 Budnik I, Brill A. Immune Factors in Deep Vein Thrombosis Initiation. Trends Immunol 2018;39:610-23. [PMID: 29776849 DOI: 10.1016/j.it.2018.04.010] [Cited by in Crossref: 59] [Cited by in F6Publishing: 53] [Article Influence: 14.8] [Reference Citation Analysis]
22 Sartain SE, Turner NA, Moake JL. TNF Regulates Essential Alternative Complement Pathway Components and Impairs Activation of Protein C in Human Glomerular Endothelial Cells. J I 2016;196:832-45. [DOI: 10.4049/jimmunol.1500960] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
23 Turner NA, Sartain SE, Hui SK, Moake JL. Regulatory components of the alternative complement pathway in endothelial cell cytoplasm, factor H and factor I, are not packaged in Weibel-Palade bodies. PLoS One 2015;10:e0121994. [PMID: 25803806 DOI: 10.1371/journal.pone.0121994] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
24 Cao W, Pham HP, Williams LA, McDaniel J, Siniard RC, Lorenz RG, Marques MB, Zheng XL. Human neutrophil peptides and complement factor Bb in pathogenesis of acquired thrombotic thrombocytopenic purpura. Haematologica 2016;101:1319-26. [PMID: 27662014 DOI: 10.3324/haematol.2016.149021] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
25 Schwameis M, Schörgenhofer C, Assinger A, Steiner MM, Jilma B. VWF excess and ADAMTS13 deficiency: a unifying pathomechanism linking inflammation to thrombosis in DIC, malaria, and TTP. Thromb Haemost 2015;113:708-18. [PMID: 25503977 DOI: 10.1160/TH14-09-0731] [Cited by in Crossref: 75] [Cited by in F6Publishing: 39] [Article Influence: 9.4] [Reference Citation Analysis]
26 Levi M, Scully M, Singer M. The role of ADAMTS-13 in the coagulopathy of sepsis. J Thromb Haemost 2018;16:646-51. [PMID: 29337416 DOI: 10.1111/jth.13953] [Cited by in Crossref: 40] [Cited by in F6Publishing: 40] [Article Influence: 10.0] [Reference Citation Analysis]
27 Mikes B, Sinkovits G, Farkas P, Csuka D, Rázsó K, Réti M, Radványi G, Demeter J, Prohászka Z. Carboxiterminal pro-endothelin-1 as an endothelial cell biomarker in thrombotic thrombocytopenic purpura. Thromb Haemost 2016;115:1034-43. [PMID: 26763086 DOI: 10.1160/TH15-07-0564] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
28 Shivshankar P, Li YD, Mueller-Ortiz SL, Wetsel RA. In response to complement anaphylatoxin peptides C3a and C5a, human vascular endothelial cells migrate and mediate the activation of B-cells and polarization of T-cells. FASEB J 2020;34:7540-60. [PMID: 32301538 DOI: 10.1096/fj.201902397R] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
29 Feng S, Liang X, Cruz MA, Vu H, Zhou Z, Pemmaraju N, Dong JF, Kroll MH, Afshar-Kharghan V. The interaction between factor H and Von Willebrand factor. PLoS One 2013;8:e73715. [PMID: 23991205 DOI: 10.1371/journal.pone.0073715] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 3.8] [Reference Citation Analysis]
30 Lokki AI, Heikkinen-Eloranta J. Pregnancy induced TMA in severe preeclampsia results from complement-mediated thromboinflammation. Hum Immunol 2021;82:371-8. [PMID: 33820656 DOI: 10.1016/j.humimm.2021.03.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
31 Chen Y, Wei D, Deng M. Comparative Analysis of Serum Proteins Between Hepatitis B Virus Genotypes B and C Infection by DIA-Based Quantitative Proteomics. Infect Drug Resist 2021;14:4701-15. [PMID: 34795487 DOI: 10.2147/IDR.S335666] [Reference Citation Analysis]
32 Nolasco JG, Nolasco LH, Da Q, Cirlos S, Ruggeri ZM, Moake JL, Cruz MA. Complement Component C3 Binds to the A3 Domain of von Willebrand Factor. TH Open 2018;2:e338-45. [PMID: 31080944 DOI: 10.1055/s-0038-1672189] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
33 Yang WJ, Yang YN, Cao J, Man ZH, Li Y, Xing YQ. Paxillin regulates vascular endothelial growth factor A-induced in vitro angiogenesis of human umbilical vein endothelial cells. Mol Med Rep 2015;11:1784-92. [PMID: 25405379 DOI: 10.3892/mmr.2014.2961] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
34 Nolasco L, Nolasco J, Feng S, Afshar-kharghan V, Moake J. Human Complement Factor H Is a Reductase for Large Soluble von Willebrand Factor Multimers—Brief Report. Arterioscler Thromb Vasc Biol 2013;33:2524-8. [DOI: 10.1161/atvbaha.113.302280] [Cited by in Crossref: 26] [Cited by in F6Publishing: 14] [Article Influence: 2.9] [Reference Citation Analysis]
35 Farkas P, Csuka D, Mikes B, Sinkovits G, Réti M, Németh E, Rácz K, Madách K, Gergely M, Demeter J, Prohászka Z. Complement activation, inflammation and relative ADAMTS13 deficiency in secondary thrombotic microangiopathies. Immunobiology 2017;222:119-27. [DOI: 10.1016/j.imbio.2016.10.014] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 3.6] [Reference Citation Analysis]
36 Oncul S, Afshar-Kharghan V. The interaction between the complement system and hemostatic factors. Curr Opin Hematol 2020;27:341-52. [PMID: 32701617 DOI: 10.1097/MOH.0000000000000605] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
37 Gragnano F, Sperlongano S, Golia E, Natale F, Bianchi R, Crisci M, Fimiani F, Pariggiano I, Diana V, Carbone A, Cesaro A, Concilio C, Limongelli G, Russo M, Calabrò P. The Role of von Willebrand Factor in Vascular Inflammation: From Pathogenesis to Targeted Therapy. Mediators Inflamm 2017;2017:5620314. [PMID: 28634421 DOI: 10.1155/2017/5620314] [Cited by in Crossref: 83] [Cited by in F6Publishing: 82] [Article Influence: 16.6] [Reference Citation Analysis]
38 Goel A, Raghupathy V, Amirtharaj GJ, Chapla A, Venkatraman A, Ramakrishna B, Ramachandran A, Thomas N, Balasubramanian KA, Mackie I, Elias E, Eapen CE. ADAMTS13 missense variants associated with defective activity and secretion of ADAMTS13 in a patient with non-cirrhotic portal hypertension. Indian J Gastroenterol 2017;36:380-9. [DOI: 10.1007/s12664-017-0786-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
39 Sperati CJ, Moliterno AR. Thrombotic Microangiopathy. Hematology/Oncology Clinics of North America 2015;29:541-59. [DOI: 10.1016/j.hoc.2015.02.002] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
40 Yang S, Mcgookey M, Wang Y, Cataland SR, Wu HM. Effect of Blood Sampling, Processing, and Storage on the Measurement of Complement Activation Biomarkers. American Journal of Clinical Pathology 2015;143:558-65. [DOI: 10.1309/ajcpxpd7zqxntial] [Cited by in Crossref: 44] [Cited by in F6Publishing: 24] [Article Influence: 6.3] [Reference Citation Analysis]
41 Amari Chinchilla K, Vijayan M, Taveras Garcia B, Jim B. Complement-Mediated Disorders in Pregnancy. Adv Chronic Kidney Dis 2020;27:155-64. [PMID: 32553248 DOI: 10.1053/j.ackd.2020.01.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
42 Cataland SR, Wu HM. How I treat: the clinical differentiation and initial treatment of adult patients with atypical hemolytic uremic syndrome. Blood 2014;123:2478-84. [PMID: 24599547 DOI: 10.1182/blood-2013-11-516237] [Cited by in Crossref: 86] [Cited by in F6Publishing: 61] [Article Influence: 10.8] [Reference Citation Analysis]
43 Chapin J, Terry HS, Kleinert D, Laurence J. The role of complement activation in thrombosis and hemolytic anemias. Transfus Apher Sci 2016;54:191-8. [PMID: 27156108 DOI: 10.1016/j.transci.2016.04.008] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 5.7] [Reference Citation Analysis]
44 Roumenina LT, Rayes J, Frimat M, Fremeaux-Bacchi V. Endothelial cells: source, barrier, and target of defensive mediators. Immunol Rev 2016;274:307-29. [PMID: 27782324 DOI: 10.1111/imr.12479] [Cited by in Crossref: 54] [Cited by in F6Publishing: 56] [Article Influence: 10.8] [Reference Citation Analysis]
45 Turner N, Sartain S, Moake J. Ultralarge von Willebrand factor-induced platelet clumping and activation of the alternative complement pathway in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndromes.Hematol Oncol Clin North Am. 2015;29:509-524. [PMID: 26043389 DOI: 10.1016/j.hoc.2015.01.008] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
46 O'Brien ET, Wang Y, Ying H, Yue BY. Differential expression of genes in cells cultured from juxtacanalicular trabecular meshwork and Schlemm's canal. J Ocul Pharmacol Ther 2014;30:291-9. [PMID: 24611521 DOI: 10.1089/jop.2013.0189] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
47 Tan Y, Zhao MH. Complement in glomerular diseases. Nephrology (Carlton) 2018;23 Suppl 4:11-5. [PMID: 30298653 DOI: 10.1111/nep.13461] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
48 Turner NA, Moake JL. Factor VIII Is Synthesized in Human Endothelial Cells, Packaged in Weibel-Palade Bodies and Secreted Bound to ULVWF Strings. PLoS One 2015;10:e0140740. [PMID: 26473492 DOI: 10.1371/journal.pone.0140740] [Cited by in Crossref: 41] [Cited by in F6Publishing: 33] [Article Influence: 5.9] [Reference Citation Analysis]
49 Conway EM. Reincarnation of ancient links between coagulation and complement. J Thromb Haemost 2015;13 Suppl 1:S121-32. [PMID: 26149013 DOI: 10.1111/jth.12950] [Cited by in Crossref: 60] [Cited by in F6Publishing: 59] [Article Influence: 10.0] [Reference Citation Analysis]
50 Feng S, Liang X, Kroll MH, Chung DW, Afshar-Kharghan V. von Willebrand factor is a cofactor in complement regulation. Blood 2015;125:1034-7. [PMID: 25395424 DOI: 10.1182/blood-2014-06-585430] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 5.1] [Reference Citation Analysis]
51 Wijeratne SS, Nolasco L, Li J, Jiang K, Moake JL, Kiang CH. Correlating Conformational Dynamics with the Von Willebrand Factor Reductase Activity of Factor H Using Single Molecule Force Measurements. J Phys Chem B 2018;122:10653-8. [PMID: 30351116 DOI: 10.1021/acs.jpcb.8b06153] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
52 Zlobina KE, Guria GT. Platelet activation risk index as a prognostic thrombosis indicator. Sci Rep 2016;6:30508. [PMID: 27461235 DOI: 10.1038/srep30508] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
53 Zheng L, Zhang D, Cao W, Song WC, Zheng XL. Synergistic effects of ADAMTS13 deficiency and complement activation in pathogenesis of thrombotic microangiopathy. Blood 2019;134:1095-105. [PMID: 31409673 DOI: 10.1182/blood.2019001040] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
54 Rayes J, Roumenina LT, Dimitrov JD, Repessé Y, Ing M, Christophe O, Jokiranta TS, Halbwachs-Mecarelli L, Borel-Derlon A, Kaveri SV, Frémeaux-Bacchi V, Lacroix-Desmazes S. The interaction between factor H and VWF increases factor H cofactor activity and regulates VWF prothrombotic status. Blood 2014;123:121-5. [PMID: 24014239 DOI: 10.1182/blood-2013-04-495853] [Cited by in Crossref: 46] [Cited by in F6Publishing: 43] [Article Influence: 5.1] [Reference Citation Analysis]
55 Kölm R, Schaller M, Roumenina LT, Niemiec I, Kremer Hovinga JA, Khanicheh E, Kaufmann BA, Hopfer H, Trendelenburg M. Von Willebrand Factor Interacts with Surface-Bound C1q and Induces Platelet Rolling. J Immunol 2016;197:3669-79. [PMID: 27698012 DOI: 10.4049/jimmunol.1501876] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
56 Fujimura Y, Holland LZ. COVID-19 microthrombosis: unusually large VWF multimers are a platform for activation of the alternative complement pathway under cytokine storm. Int J Hematol 2022. [PMID: 35316498 DOI: 10.1007/s12185-022-03324-w] [Reference Citation Analysis]
57 Prohászka Z, Nilsson B, Frazer-Abel A, Kirschfink M. Complement analysis 2016: Clinical indications, laboratory diagnostics and quality control. Immunobiology 2016;221:1247-58. [PMID: 27475991 DOI: 10.1016/j.imbio.2016.06.008] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 7.3] [Reference Citation Analysis]
58 Chang JC. Sepsis and septic shock: endothelial molecular pathogenesis associated with vascular microthrombotic disease. Thromb J 2019;17:10. [PMID: 31160889 DOI: 10.1186/s12959-019-0198-4] [Cited by in Crossref: 58] [Cited by in F6Publishing: 57] [Article Influence: 19.3] [Reference Citation Analysis]
59 Schröder-Braunstein J, Kirschfink M. Complement deficiencies and dysregulation: Pathophysiological consequences, modern analysis, and clinical management. Mol Immunol 2019;114:299-311. [PMID: 31421540 DOI: 10.1016/j.molimm.2019.08.002] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
60 Du J, Yang Q, Luo L, Yang D. C1qr and C1qrl redundantly regulate angiogenesis in zebrafish through controlling endothelial Cdh5. Biochem Biophys Res Commun 2017;483:482-7. [PMID: 28007601 DOI: 10.1016/j.bbrc.2016.12.118] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
61 Sartain SE, Turner NA, Moake JL. Brain microvascular endothelial cells exhibit lower activation of the alternative complement pathway than glomerular microvascular endothelial cells. J Biol Chem 2018;293:7195-208. [PMID: 29555686 DOI: 10.1074/jbc.RA118.002639] [Cited by in Crossref: 23] [Cited by in F6Publishing: 10] [Article Influence: 5.8] [Reference Citation Analysis]
62 Bitzan M, Hammad RM, Bonnefoy A, Al Dhaheri WS, Vézina C, Rivard GÉ. Acquired thrombotic thrombocytopenic purpura with isolated CFHR3/1 deletion-rapid remission following complement blockade. Pediatr Nephrol 2018;33:1437-42. [PMID: 29728803 DOI: 10.1007/s00467-018-3957-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
63 Tati R, Kristoffersson AC, Ståhl AL, Rebetz J, Wang L, Licht C, Motto D, Karpman D. Complement activation associated with ADAMTS13 deficiency in human and murine thrombotic microangiopathy. J Immunol 2013;191:2184-93. [PMID: 23878316 DOI: 10.4049/jimmunol.1301221] [Cited by in Crossref: 46] [Cited by in F6Publishing: 45] [Article Influence: 5.1] [Reference Citation Analysis]
64 Herbig BA, Diamond SL. Pathological von Willebrand factor fibers resist tissue plasminogen activator and ADAMTS13 while promoting the contact pathway and shear-induced platelet activation. J Thromb Haemost 2015;13:1699-708. [PMID: 26178390 DOI: 10.1111/jth.13044] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 4.1] [Reference Citation Analysis]
65 Donat C, Thanei S, Trendelenburg M. Binding of von Willebrand Factor to Complement C1q Decreases the Phagocytosis of Cholesterol Crystals and Subsequent IL-1 Secretion in Macrophages. Front Immunol 2019;10:2712. [PMID: 31824501 DOI: 10.3389/fimmu.2019.02712] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]